Virginia Beach, Va. (Aug. 1, 2022) - LifeNet Health LifeSciences, a leader in all-human biomedical research solutions, is launching a new Cell-Based Assay Service following the acquisition of biotechnology firm IONTOX. These new in vitro screening options offer alternatives to animal testing that support safer, more effective novel compound discovery – providing a new level of human relevance and predictability, while furthering LifeNet Health’s commitment to improve lives through the gift of donation.
The new services from LifeNet Health LifeSciences include:
Read More- Featuring pre-clinical research solutions to include an all-human triculture model, thyrocytes for use in 3D models, and genotyped human hepatocytes
- A series of engaging events during SOT will offer researchers opportunities to connect directly with LifeNet Health LifeSciences subject matter experts
Virginia Beach, Va. (March 21, 2022) – LifeNet Health LifeSciences, a leader in all-human biomedical research so
Read MoreMarch 16, 2021
Austin, Texas, USA, March 16, 2021 -- Pure MHC, LLC, a target discovery and development company, today announced the launch of its Peptide HLA Immunotherapy Data Resource (“PHIDR”), built through its collaboration with a trusted provider of transplant solutions and a leader in regenerative medicine, LifeNet Health.
Read MoreMarch 12, 2021
VIRGINIA BEACH, Va. (March 12, 2021) — LifeNet Health LifeSciences will showcase its portfolio of innovative human cell- and tissue-based research solutions — including the new, all-human Tri-Culture model, thyrocytes for use in 3D models and genotyped human hepatocytes — at the Society of Toxicology (SOT) virtual annual meeting and ToxExpo at booth #1322. LifeSciences provides researchers human-relevant research solutions to optimize outcomes and speed the drug discovery process.
Read MoreFebruary 3, 2021
VIRGINIA BEACH, Va. (Feb. 3, 2021) — LifeNet Health LifeSciences has successfully isolated three types of primary human lung epithelial cells from a single donor. One of the three types, alveolar epithelial type II cells, are of particular interest to scientists due to their applicability for respiratory disease research. LifeNet Health’s scientists have also isolated the bronchial and small airway epithelial cells, which are critical for the first lines of defense in protecting the lungs.
Read MoreJanuary 13, 2021
VIRGINIA BEACH, Va. — LifeNet Health announced today the launch of their newly expanded LifeSciences division which is offering human cell- and tissue-based research solutions through a new website, LNHLifeSciences.org.
Read MoreNovember 07, 2019
Virginia Beach, VA. - LifeNet Health, the world's leading provider of regenerative medicine solutions, has acquired the assets of Samsara Sciences, a San Diego-based life sciences company specializing in human primary liver and kidney cell isolation. The acquisition includes Samsara's equipment, inventory and associated technology.
Read MoreJune 03, 2019
PHILADELPHIA, Pa., (June 3, 2019) — LifeNet Health (Booth #3649) will feature its portfolio of premium research solutions, including high-quality human primary hepatocytes and islets, at the BIO International Convention June 3-6 in Philadelphia.
Read MoreMay 14, 2019
SAN DIEGO, Calif. - May 14, 2019 - LifeNet Health, the world’s leading provider of regenerative medicine solutions, today announced the opening of a San Diego facility that stands as a Center of Excellence for its life sciences and tissue-engineering programs, as well as a logistical hub for hospital and surgeon clients on the West Coast.
Read MoreJune 04, 2018
Boston, Mass. — June 4, 2018 — LifeNet Health will feature its growing portfolio of unique, high-quality biospecimens for research at the BIO International Convention June 4-7 in Boston (Booth #2414).
Through its LifeSciences Division, the regenerative medicine company is focused on providing transplant- quality organs and tissues, innovative drug discovery platforms and isolated primary cells.
Read More